drugset / Trial / NCT02241759

Study of the Electrocardiographic Effects of TA-8995

NCT02241759

Phase 1 Completed 136 enrolled Xention Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.

Timeline

Start
2014-08
Primary completion
2014-11
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Obicetrapib Small molecule 150 mg Oral

Indications